5-Substituted tetrazoles as bioisosteres of carboxylic acids. Bioisosterism and mechanistic studies on glutathione reductase inhibitors as antimalarials

Journal of Medicinal Chemistry

Volumn 47, Issue 24, 2004, Pages 5972-5983

  Biot, Christophe ^a   Bauer, Holger ^b,c   Schirmer, R Heiner ^c   Davioud Charvet, Elisabeth ^b,c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIV LILLE   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 [4 (1H TETRAZOL 5 YL)BUTYL][1,4]NAPHTHOQUINONE; 3 [5 [4 [2' (3' METHYL) 1',4' NAPHTHOQUINOLYL]BUTYL]TETRAZOL 1 YL]PROPIONITRILE; 5 [2' (3' METHYL) 1',4' NAPHTHOQUINOLYL]PENTANOIC ACID (2 CYANOETHYL)AMIDE; 6 [2' (3' METHYL) 1',4' NAPHTHOQUINOLYL]HEXANOIC ACID; ANTIMALARIAL AGENT; CARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; GLUTATHIONE DISULFIDE; GLUTATHIONE REDUCTASE; GLUTATHIONE REDUCTASE INHIBITOR; MENADIONE; METHYLENE BLUE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AB INITIO CALCULATION; ACIDITY; ANTIMALARIAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; COMPETITIVE INHIBITION; DRUG MECHANISM; ENZYME CONFORMATION; ENZYME INHIBITION; ERYTHROCYTE; PLASMODIUM FALCIPARUM; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CELL LINE; DRUG RESISTANCE; GLUTATHIONE REDUCTASE; HEXANOIC ACIDS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHOQUINONES; PLASMODIUM FALCIPARUM; PRODRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 8644263983     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0497545     Document Type: Article

References (47)

1. Schirmer, R. H.; Müller, J. G.; Krauth-Siegel, R. L. Disulfide reductase inhibitors as chemotherapeutic agents: the design of drugs for trypanosomiasis and malaria. Angew. Chem., Int. Ed. Engl. 1995, 34, 141-154.
2. Krauth-Siegel, R. L.; Bauer, H.; Schirmer, R. H. Dithiol proteins as guardians of the intracellular redox milieu in parasites. Old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem., Int. Ed. Engl., in press.
3. Ginsburg, H.; Famin, O.; Zhang, J.; Krugliak, M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol. 1998, 56, 1305-1313.
4. Meierjohann, S.; Walter, R. D.; Müller, S. Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochem. J. 2002, 368, 761-768.
5. Deharo, E.; Barkan, D.; Krugliak, M.; Golenser, J.; Ginsburg H. Potentiation of the antimalarial action of chloroquine in rodent malaria by drugs known to reduce cellular glutathione levels. Biochem. Pharmacol. 2003, 66, 809-817.
6. Sarma, G. N.; Savvides, S. N.; Becker, K.; Schirmer, M.; Schirmer, R. H.; Karplus, P. A. Glutathione reductase of the malarial parasite Plasmodium falciparum: crystal structure and inhibitor development. J. Mol. Biol. 2003, 328, 893-907.
7. Karplus, P. A.; Pai, E. F.; Schulz, G. E. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. Eur. J. Biochem. 1989, 178, 693-703.
8. Davioud-Charvet, E.; Delarue, S.; Biot, C.; Schwöbel, B.; Böhme, C. C.; Müssigbrodt, A.; Maes, L.; Sergheraert, C.; Grellier, P.; Schirmer, R. H.; Becker, K. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem. 2001, 44, 4268-4276.
9. Herr, R. J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg. Med. Chem. 2002, 10, 3379-3393.
10. Koguro, K.; Oga, T.; Mitsui, S.; Orita, R. Novel synthesis of 5-substituted tetrazoles from nitriles. Synthesis 1998, 910-914.
11. De Lombaert, S.; Blanchard, L.; Stamford, L. B.; Tan, J.; Wallace, E. M.; Satoh, Y., Fitt; J., Hoyer, D.; Simonsbergen, D.; Moliterni, J.; Marcopoulos, N.; Savage, P.; Chou, M.; Trapani, A. J.; Jeng, A. Y. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action. J. Med. Chem. 2000, 43, 488-504.
12. Biot, C.; Dessolin, J.; Grellier, P.; Davioud-Charvet, E. Double-drug development against antioxidant enzymes from Plasmodium falciparum. Redox Rep. 2003, 8, 280-283.
13. Cornish-Bowden, A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J. 1974, 137, 143-144.
14. Nordhoff, A. Zur planvollen Entwicklung von Inhibitoren der obligat dimeren Glutathionreduktasen des Menschen und der Maus. Evaluierung potentieller Chemotherapeutika und Ansätze zur Hemmung der Dimerisierung. Ph.D. Thesis, Heidelberg University, 1995.
15. Blumenstiel, K.; Schöneck, R.; Yardley, V.; Croft, S. L.; Krauth-Siegel, R. L. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem. Pharmacol. 1999, 58, 1791-1799.
16. Karplus, P. A.; Schulz, G. E. Refined structure of glutathione reductase at 1.54 Å resolution. J. Mol. Biol. 1987, 195, 701-729.
17. Karplus, P. A.; Pai, E. F.; Schulz, G. E. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. Eur. J. Biochem. 1989, 178, 693-703.
18. Savvides, S.; Karplus, P. A. Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J. Biol. Chem. 1996, 271, 8101-8107.
19. Schönleben-Janas, A.; Kirsch, P.; Mittl, P. R. E.; Schirmer, R. H.; Krauth-Siegel, L. Inhibition of human glutathione reductase by 10-arylisoalloxazines: crystallographic, kinetic, and electrochemical studies. J. Med. Chem. 1996, 39, 1549-1554.
20. Krauth-Siegel, R. L.; Arscott, L. D.; Schönleben-Janas, A.; Schirmer, R. H.; Williams, C. H. Role of active site tyrosine residues in catalysis by human glutathione reductase. Biochemistry 1998, 37, 13968-13977.
21. Zappe, H. Die Bindungsstellen hämolyseinduzierender Pharmaka an der Glutathionreduktase aus menschlichen Erythrocyten. M.D. thesis, Heidelberg University, 1980.
22. Politzer, P.; Truhlar, D. G. Chemical Applications of Molecular and Electrostatic Potentials; Politzer, P., Truhlar, D. G., Eds.; Plenum Press: New York, 1981.
23. Chanteux, H.; Paternotte, I.; Mingeot-Leclercq, M. P.; Brasseur, R.; Sonveaux, E.; Tulkens, P. M. Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. Pharm. Res. 2003, 20, 624-631.
24. Biot, C. Ferroquine: a new weapon in the fight against malaria. Curr. Med. Chem. 2004, 3, 135-148.
25. Wermuth, C. G. Designing prodrugs and bioprecursors. In The practice of medicinal chemistry, 2nd ed.; Wermuth, C. G., Ed.; Academic Press: London, 2003; pp 561-585.
26. Beria, I.; Nesi, M. Syntheses of brostallicin starting from distamycin A. Tetrahedron Lett. 2002, 43, 7323-7327.
27. Evans, D. A.; Barrow, J. C.; Watson, P. S.; Ratz, A. M.; Dinsmore, C. J.; Evrard, D. A.; DeVries, K. M.; Ellman, J. A.; Rychnovsky, S. D.; Lacour, J. Approaches to the synthesis of the vancomycin antibiotics. Synthesis of orienticin C (bis-dechlorovancomycin) aglycon. J. Am. Chem. Soc. 1997, 119, 3419-3420.
28. Evans, D. A.; Katz, J. L.; Peterson, G. S.; Hintermann, T. Total synthesis of teicoplanin aglycon. J. Am. Chem. Soc. 2001, 123, 12411-12413.
29. 3 at physiological pH. J. Biol. Chem. 2003, 278, 11931-11936.
30. Heerding, J. M.; Lampe, J. W.; Darges, J. W.; Stamper, M. L. Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacements. Bioorg. Med. Chem. Lett. 1995, 5, 1839-1842.
31. Cornish-Bowden, A. Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides. FEBS Lett. 1986, 203, 3-6.
32. Segel, I. H. (1975) In Enzyme Kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems; John Wiley and Sons: New York, 1975.
33. Böhme, C. C.; Arscott, L. D.; Becker, K.; Schirmer, R. H.; Williams, C. H., Jr. Kinetic characterization of glutathione reductase from the malarial parasite Plasmodium falciparum. Comparison with the human enzyme. J. Biol. Chem. 2000, 275, 37317-37323.
34. Eisenthal, R.; Cornish-Bowden, A. Prospects for antiparasitic drugs. The case of Trypanosoma brucei, the causative agent of African sleeping sickness. J. Biol. Chem. 1998, 273, 5500-5505.
35. Gallwitz, H.; Bonse, S.; Martinez-Cruz, A.; Schlichting, I.; Schumacher, K.; Krauth-Siegel, R. L. Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies. J. Med. Chem. 1999, 42, 364-372.
36. Cenas, N.; Bironaite, D.; Diekancaite, E.; Anusevicius, Z.; Sarlauska, J.; Blanchard, J. S. Chinifur, a selective inhibitor and "subversive substrate" for Trypanosoma congolense trypanothione reductase. Biochem. Biophys. Res. Commun. 1994, 204, 224-229.
37. Cenas, N. K.; Arscott, D.; Williams, C. H., Jr.; Blanchard, J. S. Mechanism of reduction of quinones by Trypanosoma congolense trypanothione reductase. Biochemistry 1994, 33, 2509-2515.
38. Bonse, S.; Richards, J. M.; Ross, S. A.; Lowe, G.; Krauth-Siegel, R. L. (2,2′:6′,2″-terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. J. Med. Chem. 2000, 43, 4812-4821.
39. Nordhoff, A.; Bücheier, U. S.; Werner, D.; Schirmer, R. H.Folding of the four domains and dimerization are impaired by the Gly446→Glu exchange in human glutathione reductase. Implications for the design of antiparasitic drugs. Biochemistry 1993, 32, 4060-4066.
40. Färber, P. M.; Arscott, L. D.; Williams, C. H., Jr.; Becker, K.; Schirmer, R. H. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett. 1998, 422, 311-314.
41. Salmon-Chemin, L.; Buisine, E.; Yardley, V.; Kohler, S.; Debreu, M. A.; Landry, V.; Sergheraert, C.; Croft, S. L.; Krauth-Siegel, L. R.; Davioud-Charvet, E. 2- and 3-Substituted-1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J. Med. Chem. 2001, 44, 548-565.
42. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A.; Stratmann, R. E., Jr.; Burant, J. C.; Dapprich, S.; Millam J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Cioslowski, J.; Ortiz, J. V.; Baboul, A. G.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; Replogle, S.; Pople, J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, PA, 1988.
43. http://www2.chemie.uni-erlangen.de/software/corina/.
44. Ditchfield, R.; Hehre, W. J.; Pople, J. A. Self-consistent molecular-orbital methods. IX. An extended Gaussian-type basis for molecular-orbital studies of organic molecules. J. Chem. Phys. 1971, 54, 724-728.
45. Harinharan, P. C.; Pople, J. A. The influence of polarization functions on molecular orbital hydrogenation energies. Theor. Chim. Acta 1973, 28, 213-222.
46. Møller, C.; Plesset, M. S. Note on the approximation treatment for many-electron systems. Phys. Rev. 1934, 46, 618-622.
47. MOLEKEL 4.0, P. Flükiger, H. P. Lüthi, S. Portmann, J. Weber, Swiss Center for Scientific Computing, Manno (Switzerland), 2000. See http://www.cscs.ch/molekel/.